Timothy P. Walbert - Oct 6, 2023 Form 4 Insider Report for Horizon Therapeutics Public Ltd Co (HZNP)

Signature
/s/ Patrick McIlvenny, Attorney-in-Fact
Stock symbol
HZNP
Transactions as of
Oct 6, 2023
Transactions value $
-$101,907,909
Form type
4
Date filed
10/6/2023, 05:57 PM
Previous filing
Jun 29, 2023
Next filing
Apr 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HZNP Ordinary Shares Disposed to Issuer -$71.9M -617K -100% $116.50 0 Oct 6, 2023 Direct F1, F2
transaction HZNP Ordinary Shares Disposed to Issuer -$12.6M -108K -100% $116.50 0 Oct 6, 2023 See Footnote F2, F3
transaction HZNP Ordinary Shares Disposed to Issuer -$11.7M -100K -100% $116.50 0 Oct 6, 2023 See Footnote F2, F4
transaction HZNP Ordinary Shares Disposed to Issuer -$5.82M -49.9K -100% $116.50 0 Oct 6, 2023 By Spouse F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HZNP Stock Option (Right to Buy) Disposed to Issuer -743K -100% 0 Oct 6, 2023 Ordinary Shares 743K $22.14 Direct F5, F6
transaction HZNP Stock Option (Right to Buy) Disposed to Issuer -1.65M -100% 0 Oct 6, 2023 Ordinary Shares 1.65M $28.53 Direct F5, F6
transaction HZNP Restricted Stock Units Disposed to Issuer -34.9K -100% 0 Oct 6, 2023 Ordinary Shares 34.9K Direct F7, F8, F9
transaction HZNP Restricted Stock Units Disposed to Issuer -49.2K -100% 0 Oct 6, 2023 Ordinary Shares 49.2K Direct F7, F9, F10
transaction HZNP Restricted Stock Units Disposed to Issuer -71.3K -100% 0 Oct 6, 2023 Ordinary Shares 71.3K Direct F7, F9, F11
transaction HZNP Performance Restricted Stock Units Disposed to Issuer -45.8K -100% 0 Oct 6, 2023 Ordinary Shares 45.8K Direct F7, F12, F13
transaction HZNP Performance Restricted Stock Units Disposed to Issuer -17.4K -100% 0 Oct 6, 2023 Ordinary Shares 17.4K Direct F7, F12, F13
transaction HZNP Performance Restricted Stock Units Disposed to Issuer -105K -100% 0 Oct 6, 2023 Ordinary Shares 105K Direct F7, F12, F13
transaction HZNP Performance Restricted Stock Units Disposed to Issuer -14.8K -100% 0 Oct 6, 2023 Ordinary Shares 14.8K Direct F7, F13, F14
transaction HZNP Performance Restricted Stock Units Disposed to Issuer -44.3K -100% 0 Oct 6, 2023 Ordinary Shares 44.3K Direct F7, F13, F15
transaction HZNP Performance Restricted Stock Units Disposed to Issuer -73.8K -100% 0 Oct 6, 2023 Ordinary Shares 73.8K Direct F7, F13, F15
transaction HZNP Performance Restricted Stock Units Disposed to Issuer -35.6K -100% 0 Oct 6, 2023 Ordinary Shares 35.6K Direct F7, F13, F16
transaction HZNP Performance Restricted Stock Units Disposed to Issuer -17.8K -100% 0 Oct 6, 2023 Ordinary Shares 17.8K Direct F7, F13, F17
transaction HZNP Performance Restricted Stock Units Disposed to Issuer -17.8K -100% 0 Oct 6, 2023 Ordinary Shares 17.8K Direct F7, F13, F17
transaction HZNP Restricted Stock Units Disposed to Issuer -4.66K -100% 0 Oct 6, 2023 Ordinary Shares 4.66K By Spouse F7, F9, F12
transaction HZNP Restricted Stock Units Disposed to Issuer -14.3K -100% 0 Oct 6, 2023 Ordinary Shares 14.3K By Spouse F7, F9, F10
transaction HZNP Restricted Stock Units Disposed to Issuer -20.7K -100% 0 Oct 6, 2023 Ordinary Shares 20.7K By Spouse F7, F9, F11
transaction HZNP Performance Restricted Stock Units Disposed to Issuer -21.4K -100% 0 Oct 6, 2023 Ordinary Shares 21.4K By Spouse F7, F13, F15
transaction HZNP Performance Restricted Stock Units Disposed to Issuer -12.9K -100% 0 Oct 6, 2023 Ordinary Shares 12.9K By Spouse F7, F13, F15
transaction HZNP Performance Restricted Stock Units Disposed to Issuer -4.29K -100% 0 Oct 6, 2023 Ordinary Shares 4.29K By Spouse F7, F13, F14
transaction HZNP Performance Restricted Stock Units Disposed to Issuer -10.3K -100% 0 Oct 6, 2023 Ordinary Shares 10.3K By Spouse F7, F13, F16
transaction HZNP Performance Restricted Stock Units Disposed to Issuer -5.17K -100% 0 Oct 6, 2023 Ordinary Shares 5.17K By Spouse F13, F17
transaction HZNP Performance Restricted Stock Units Disposed to Issuer -5.17K -100% 0 Oct 6, 2023 Ordinary Shares 5.17K By Spouse F7, F13, F17
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Timothy P. Walbert is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Includes 279 Ordinary Shares (as defined in footnote 2 of this Form 4) acquired by the reporting person on June 1, 2023 pursuant to an employee stock purchase program.
F2 Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration").
F3 The Ordinary Shares are held by the Timothy P. Walbert 2021 Gift Trust, of which the Reporting Person's spouse is the Trustee and beneficiary.
F4 The Ordinary Shares are held by the Keli B. Walbert 2021 Gift Trust, of which the Reporting Person is the Trustee. The beneficiaries of the Trust include the Reporting Person and his descendants.
F5 The Option (as defined in footnote 6 to this Form 4) is fully vested.
F6 Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option.
F7 Each RSU (as defined in footnote 9 to this Form 4) and PSU (as defined in footnote 13 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer.
F8 The Ordinary Shares subject to the RSUs vest on January 5, 2024.
F9 Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs (as defined in footnote 14 to this Form 4), (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme.
F10 The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2022.
F11 The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2023.
F12 The Ordinary Shares subject to the PSUs (as defined in footnote 13 to this Form 4) vest on January 5, 2024.
F13 Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration.
F14 The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2024 and the remaining shares vest on January 5, 2025.
F15 The Ordinary Shares subject to the PSUs vest on January 5, 2025.
F16 The Ordinary Shares subject to the PSUs vest on January 5, 2026.
F17 The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026.